Ascendis Pharma A/S
ASND
Classificação em ações
#1508
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Preço da ação
$230.45
Última sincronização: 2026-10-19
Valor de mercado
$14.37B
Variação (1 dia)
2.31%
Variação (1 ano)
12.30%
País
DK
Negociar Ascendis Pharma A/S (ASND)
Categoria
Healthcare
Lucros da Ascendis Pharma A/S (ASND)
Lucros em Jun 2026 TTM: $119.93M
De acordo com os últimos relatórios financeiros da Ascendis Pharma A/S, os ganhos atuais da empresa são de $119.93M. Em 2024, a empresa teve ganhos de $-388.38M, um aumento em relação a aos ganhos de 2023, que foram de $-524.15M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Ascendis Pharma A/S de 2012 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $119.93M | -150.04% |
| 2025 | $-239.65M | -38.30% |
| 2024 | $-388.38M | -25.90% |
| 2023 | $-524.15M | -15.43% |
| 2022 | $-619.81M | 41.96% |
| 2021 | $-436.60M | -14.48% |
| 2020 | $-510.50M | 108.47% |
| 2019 | $-244.87M | 63.30% |
| 2018 | $-149.95M | 0.48% |
| 2017 | $-149.24M | 106.36% |
| 2016 | $-72.32M | 98.38% |
| 2015 | $-36.46M | 191.39% |
| 2014 | $-12.51M | -293.36% |
| 2013 | $6.47M | 281.71% |
| 2012 | $1.70M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | 4,298.37% |
US
|
|
| $-3.09B | -2,674.04% |
US
|
|
| $-4.02B | -3,448.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,526.51% |
NL
|
